Expanded therapeutic potential in activity space of next-generation 5-nitroimidazole antimicrobials with broad structural diversity

Yukiko Miyamoto, Jarosław Kalisiak, Keith Korthals, Tineke Lauwaet, Dae Young Cheung, Ricardo Lozano, Eduardo R. Cobo, Peter Upcroft, Jacqueline A. Upcroft, Douglas E. Berg, Frances D. Gillin, Valery V. Fokin, K. Barry Sharpless, Lars Eckmann

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Metronidazole and other 5-nitroimidazoles (5-NI) are among the most effective antimicrobials available against many important anaerobic pathogens, but evolving resistance is threatening their long-term clinical utility. The common 5-NIs were developed decades ago, yet little 5-NI drug development has since taken place, leaving the true potential of this important drug class unexplored. Here we report on a unique approach to the modular synthesis of diversified 5-NIs for broad exploration of their antimicrobial potential. Many of the more than 650 synthesized compounds, carrying structurally diverse functional groups, have vastly improved activity against a range of microbes, including the pathogenic protozoa Giardia lamblia and Trichomonas vaginalis, and the bacterial pathogens Helicobacter pylori, Clostridium difficile, and Bacteroides fragilis. Furthermore, they can overcome different forms of drug resistance, and are active and nontoxic in animal infection models. These findings provide impetus to the development of structurally diverse, next-generation 5-NI drugs as agents in the antimicrobial armamentarium, thus ensuring their future viability as primary therapeutic agents against many clinically important infections.

Original languageEnglish
Pages (from-to)17564-17569
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume110
Issue number43
DOIs
Publication statusPublished - 22 Oct 2013
Externally publishedYes

Fingerprint

Pharmaceutical Preparations
Trichomonas vaginalis
Bacteroides fragilis
Giardia lamblia
Clostridium difficile
Metronidazole
Anti-Infective Agents
Infection
Drug Resistance
Helicobacter pylori
Therapeutics
Animal Models
4-nitroimidazole

Keywords

  • Antibiotics
  • Infectious diseases
  • Medicinal chemistry

ASJC Scopus subject areas

  • General

Cite this

Expanded therapeutic potential in activity space of next-generation 5-nitroimidazole antimicrobials with broad structural diversity. / Miyamoto, Yukiko; Kalisiak, Jarosław; Korthals, Keith; Lauwaet, Tineke; Cheung, Dae Young; Lozano, Ricardo; Cobo, Eduardo R.; Upcroft, Peter; Upcroft, Jacqueline A.; Berg, Douglas E.; Gillin, Frances D.; Fokin, Valery V.; Sharpless, K. Barry; Eckmann, Lars.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 110, No. 43, 22.10.2013, p. 17564-17569.

Research output: Contribution to journalArticle

Miyamoto, Y, Kalisiak, J, Korthals, K, Lauwaet, T, Cheung, DY, Lozano, R, Cobo, ER, Upcroft, P, Upcroft, JA, Berg, DE, Gillin, FD, Fokin, VV, Sharpless, KB & Eckmann, L 2013, 'Expanded therapeutic potential in activity space of next-generation 5-nitroimidazole antimicrobials with broad structural diversity', Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 43, pp. 17564-17569. https://doi.org/10.1073/pnas.1302664110
Miyamoto, Yukiko ; Kalisiak, Jarosław ; Korthals, Keith ; Lauwaet, Tineke ; Cheung, Dae Young ; Lozano, Ricardo ; Cobo, Eduardo R. ; Upcroft, Peter ; Upcroft, Jacqueline A. ; Berg, Douglas E. ; Gillin, Frances D. ; Fokin, Valery V. ; Sharpless, K. Barry ; Eckmann, Lars. / Expanded therapeutic potential in activity space of next-generation 5-nitroimidazole antimicrobials with broad structural diversity. In: Proceedings of the National Academy of Sciences of the United States of America. 2013 ; Vol. 110, No. 43. pp. 17564-17569.
@article{3944c7b099c94d7b9e2390360833bb93,
title = "Expanded therapeutic potential in activity space of next-generation 5-nitroimidazole antimicrobials with broad structural diversity",
abstract = "Metronidazole and other 5-nitroimidazoles (5-NI) are among the most effective antimicrobials available against many important anaerobic pathogens, but evolving resistance is threatening their long-term clinical utility. The common 5-NIs were developed decades ago, yet little 5-NI drug development has since taken place, leaving the true potential of this important drug class unexplored. Here we report on a unique approach to the modular synthesis of diversified 5-NIs for broad exploration of their antimicrobial potential. Many of the more than 650 synthesized compounds, carrying structurally diverse functional groups, have vastly improved activity against a range of microbes, including the pathogenic protozoa Giardia lamblia and Trichomonas vaginalis, and the bacterial pathogens Helicobacter pylori, Clostridium difficile, and Bacteroides fragilis. Furthermore, they can overcome different forms of drug resistance, and are active and nontoxic in animal infection models. These findings provide impetus to the development of structurally diverse, next-generation 5-NI drugs as agents in the antimicrobial armamentarium, thus ensuring their future viability as primary therapeutic agents against many clinically important infections.",
keywords = "Antibiotics, Infectious diseases, Medicinal chemistry",
author = "Yukiko Miyamoto and Jarosław Kalisiak and Keith Korthals and Tineke Lauwaet and Cheung, {Dae Young} and Ricardo Lozano and Cobo, {Eduardo R.} and Peter Upcroft and Upcroft, {Jacqueline A.} and Berg, {Douglas E.} and Gillin, {Frances D.} and Fokin, {Valery V.} and Sharpless, {K. Barry} and Lars Eckmann",
year = "2013",
month = "10",
day = "22",
doi = "10.1073/pnas.1302664110",
language = "English",
volume = "110",
pages = "17564--17569",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "43",

}

TY - JOUR

T1 - Expanded therapeutic potential in activity space of next-generation 5-nitroimidazole antimicrobials with broad structural diversity

AU - Miyamoto, Yukiko

AU - Kalisiak, Jarosław

AU - Korthals, Keith

AU - Lauwaet, Tineke

AU - Cheung, Dae Young

AU - Lozano, Ricardo

AU - Cobo, Eduardo R.

AU - Upcroft, Peter

AU - Upcroft, Jacqueline A.

AU - Berg, Douglas E.

AU - Gillin, Frances D.

AU - Fokin, Valery V.

AU - Sharpless, K. Barry

AU - Eckmann, Lars

PY - 2013/10/22

Y1 - 2013/10/22

N2 - Metronidazole and other 5-nitroimidazoles (5-NI) are among the most effective antimicrobials available against many important anaerobic pathogens, but evolving resistance is threatening their long-term clinical utility. The common 5-NIs were developed decades ago, yet little 5-NI drug development has since taken place, leaving the true potential of this important drug class unexplored. Here we report on a unique approach to the modular synthesis of diversified 5-NIs for broad exploration of their antimicrobial potential. Many of the more than 650 synthesized compounds, carrying structurally diverse functional groups, have vastly improved activity against a range of microbes, including the pathogenic protozoa Giardia lamblia and Trichomonas vaginalis, and the bacterial pathogens Helicobacter pylori, Clostridium difficile, and Bacteroides fragilis. Furthermore, they can overcome different forms of drug resistance, and are active and nontoxic in animal infection models. These findings provide impetus to the development of structurally diverse, next-generation 5-NI drugs as agents in the antimicrobial armamentarium, thus ensuring their future viability as primary therapeutic agents against many clinically important infections.

AB - Metronidazole and other 5-nitroimidazoles (5-NI) are among the most effective antimicrobials available against many important anaerobic pathogens, but evolving resistance is threatening their long-term clinical utility. The common 5-NIs were developed decades ago, yet little 5-NI drug development has since taken place, leaving the true potential of this important drug class unexplored. Here we report on a unique approach to the modular synthesis of diversified 5-NIs for broad exploration of their antimicrobial potential. Many of the more than 650 synthesized compounds, carrying structurally diverse functional groups, have vastly improved activity against a range of microbes, including the pathogenic protozoa Giardia lamblia and Trichomonas vaginalis, and the bacterial pathogens Helicobacter pylori, Clostridium difficile, and Bacteroides fragilis. Furthermore, they can overcome different forms of drug resistance, and are active and nontoxic in animal infection models. These findings provide impetus to the development of structurally diverse, next-generation 5-NI drugs as agents in the antimicrobial armamentarium, thus ensuring their future viability as primary therapeutic agents against many clinically important infections.

KW - Antibiotics

KW - Infectious diseases

KW - Medicinal chemistry

UR - http://www.scopus.com/inward/record.url?scp=84886416314&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886416314&partnerID=8YFLogxK

U2 - 10.1073/pnas.1302664110

DO - 10.1073/pnas.1302664110

M3 - Article

VL - 110

SP - 17564

EP - 17569

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 43

ER -